Who owns Aspire Biopharma Holdings, Inc. (ASBP)? Elite investor 13F holders
2 tracked elite investors reported holding Aspire Biopharma Holdings, Inc as of 2026-06-30, including Saba Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital | ASPIRE BIOPHARMA HLDGS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 22918.00 USD | 983603.000000 | Shares | hold | Original filing |
| D.E. Shaw | ASPIRE BIOPHARMA HLDGS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 4100.00 USD | 199999.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.